The clinical validation of Affilin® drugs is essential for sustaining its success. To this end, Scil Proteins pursues two models: Own Affilin® product development until Phase I/II and Affilin® development with partners that have special indication know-how.
Affilin® product developments currently focus on cancer and inflammation, both of which retain attractive market opportunities because patients still suffer from poor treatment. By employing the unique features, Scil Proteins aims to develop drugs with higher efficacy than current therapeutics.
